Samsung Biologics and Kineta strike cancer immunotherapy development and manufacturing deal
_scaled.jpg)
Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours
Korean contract development and manufacturing organisation Samsung Biologics and biotech Kineta have signed a strategic partnership agreement to support IND (investigational new drug) filing for Kineta’s novel anti-VISTA antibody, KVA12.1, for the treatment of solid tumours.
The CDMO will provide a range of services from cell line development, clinical drug substance, and drug product manufacturing.
The manufacturing cell line will be developed with support from Samsung Biologics’ first US R&D Center in San Francisco, which opened in October 2020. The corresponding clinical trial materials will be manufactured at Samsung Biologics' headquarters in Incheon, South Korea.
Samsung Biologics claims its CDO business brings development services at a greater speed, delivering cell line development to drug substance manufacturing in six months, and to drug product manufacturing in seven months - the "fastest" pace in the industry.
According to Shawn Iadonato, Chief Executive Officer at Kineta, the company hopes the partnership will advance KVA12.1 to IND and into first-in-human clinical trials next year.
Kineta is a clinical-stage biotech company developing novel immunotherapies in oncology.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...